Can psychedelic-assisted therapy help people heal from trauma while also repairing their closest relationships? At ICPR 2026, we sat down with clinical psychologist Anne Wagner, founder of the Remedy Institute, to discuss her pioneering research on MDMA-assisted therapy for PTSD and couples therapy, the role of connection in recovery, and the future of trauma treatment.

In September 2026, the Norwegian government announced that heroin-assisted treatment now becomes a permanent treatment option in the country. Join us on a visit to Bergen’s HABIB, one of the pilot heroin-assisted treatment programs, to learn how heroin-assisted treatment works in practice!

What happens when an altered state of consciousness becomes part of psychotherapy? We visited a new clinic in Vienna offering ketamine-assisted therapy. Dr. Claus Derganc showed us around and discussed the treatment’s potential, its risks, and how patients work through difficult experiences.

At ICPR 2024, we talked to Jamila Hokanson,from the Yale University School of Medicine, about how psychedelics might offer new hope for people living with obsessive-compulsive disorder (OCD).

I entered a residential therapeutic community in Greece expecting care, understanding and a way out of addiction. What I encountered was a culture in which humiliation, confrontation and submission could be presented as treatment. Years later, working in harm reduction and drug policy, I encountered the same institution again — this time as one of the most powerful voices shaping how Greece understood addiction and recovery. A guest article by Marios Atzemis, a leading Greek HIV activist and harm reduction expert.

At ICPR 2024, we talked to Leonie Schneider and Ian Roullier, co-founders and co-directors of the Psychedelic Participant Advocacy Network (PsyPAN) in the UK, about why patient voices matter in the development of psychedelic therapy.

What actually makes psychedelic therapy work? Is it the drug, the therapeutic setting, or the human relationship between therapist and participant? At ICPR 2026, we spoke with psychiatrist and researcher Sandeep Nayak about clinical trials, common therapeutic factors, and how the field can better understand the mechanisms behind psychedelic-assisted treatment.

At ICPR 2024, we talked to Robert Jesse, from the Johns Hopkins University, about mystical experiences with psychedelics, their spiritual and cultural dimensions, and the value of community in supporting their responsible integration.

At ICPR 2024, we talked to Wim van den Brink, MD, PhD, Professor of Psychiatry and Addiction at the Academic Medical Center, University of Amsterdam, about the potential of psychedelics to reduce compulsive thinking and support addiction treatment.

What actually makes psychedelic therapy work? Is it the drug, the therapeutic setting, or the human relationship between therapist and participant? At ICPR 2026, we spoke with psychiatrist and researcher Sandeep Nayak about clinical trials, common therapeutic factors, and how the field can better understand the mechanisms behind psychedelic-assisted treatment.